OTC
CDTX

Opera Trading Capital’s Cidara Therapeutics CDTX Stock Holding History

Opera Trading Capital’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-188
Closed -$17K – 100
2018
Q3 		$17K Buy
+188
New +$16.6K ﹤0.01% 160

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Opera Trading Capital's CDTX Position: Q4 2018 in Review

Opera Trading Capital sold out of Cidara Therapeutics (CDTX) in Q4 2018, closing a stake of 188 shares — an estimated $17K sold.

Opera Trading Capital first reported a position in CDTX in Q3 2018 and held it in 1 quarter. The position peaked at $17K in Q3 2018. 49 funds tracked by Wall St. Rank hold CDTX as of Q4 2018.

  • Opera Trading Capital reported no remaining Cidara Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Opera Trading Capital sold 188 Cidara Therapeutics shares in Q4 2018, an estimated $17K.
  • Opera Trading Capital first reported a position in Cidara Therapeutics in Q3 2018 and held it in 1 quarter.
  • Opera Trading Capital's Cidara Therapeutics position peaked at $17K in Q3 2018.
  • 49 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2018.

Based on Opera Trading Capital's 13F filing for Q4 2018, filed 22 Jan 2019.